KLRA.US Kailera Therapeutics, Inc. Common Stock

Healthcare Biotechnology USA Stocks
13.27 USD
Close of Nov 15, 2026
9.76 28.23
Market cap
USD 1.72B
P/E
-
P/B
1.67x
ROE
-37.0%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.

Is KLRA.US undervalued?

Graham number

The Graham number of Kailera Therapeutics, Inc. Common Stock cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Kailera Therapeutics, Inc. Common Stock fundamental analysis

No fundamental analysis for Kailera Therapeutics, Inc. Common Stock yet.

Kailera Therapeutics, Inc. Common Stock stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Kailera Therapeutics, Inc. Common Stock

Kailera Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company developing therapies for obesity and related conditions. The company develops clinical- and preclinical-stage therapies, with a product pipeline that includes injectable peptides, oral peptides, and oral small molecules. Key programs include KAI-9531, an injectable GLP-1/GIP receptor dual agonist; KAI-7535, an oral small molecule GLP-1 receptor agonist; and KAI-4729, an injectable GLP-1/GIP/glu…

Full company profile